Hugel Inc Cash Flow Conversion Efficiency
Hugel Inc cash flow conversion efficiency. Based on the latest financial reports, Hugel Inc (145020) has a cash flow conversion efficiency ratio of 0.038x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩40.89 Billion ≈ $27.71 Million USD) by net assets (₩1.09 Trillion ≈ $737.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Hugel Inc (2014–2025)
Cash flow conversion efficiency of Hugel Inc from 2014 to 2025. This chart illustrates how Hugel Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 145020 live share price for real-time trading data and today's change.
Hugel Inc Cash Flow Conversion Ratio Explained
Hugel Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Hugel Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hugel Inc ranked by their cash flow conversion efficiency. Also see 145020 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zensar Technologies Limited
NSE:ZENSARTECH
|
0.134x |
|
Lotte Chemical Corp
KO:011170
|
-0.034x |
|
SKAN Group AG
SW:SKAN
|
0.326x |
|
KTK Group Co Ltd
SHG:603680
|
0.004x |
|
ShanXi Coking Co Ltd
SHG:600740
|
0.010x |
|
Shanghai Liangxin Electrical Co Ltd
SHE:002706
|
0.042x |
|
Citic Offshore Helicopter Co Ltd
SHE:000099
|
0.009x |
|
Jilin Chemical Fibre Co Ltd
SHE:000420
|
0.011x |
Annual Cash Flow Conversion Efficiency for Hugel Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Hugel Inc from 2014 to 2025. Review 145020 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩980.16 Billion ≈ $664.24 Million |
₩150.06 Billion ≈ $101.69 Million |
0.153x | -13.64% |
| 2024-12-31 | ₩840.81 Billion ≈ $569.81 Million |
₩149.05 Billion ≈ $101.01 Million |
0.177x | +17.42% |
| 2023-12-31 | ₩779.68 Billion ≈ $528.38 Million |
₩117.71 Billion ≈ $79.77 Million |
0.151x | +48.32% |
| 2022-12-31 | ₩792.11 Billion ≈ $536.80 Million |
₩80.63 Billion ≈ $54.64 Million |
0.102x | -7.96% |
| 2021-12-31 | ₩777.09 Billion ≈ $526.62 Million |
₩85.94 Billion ≈ $58.24 Million |
0.111x | +11.14% |
| 2020-12-31 | ₩746.67 Billion ≈ $506.01 Million |
₩74.30 Billion ≈ $50.35 Million |
0.100x | -9.59% |
| 2019-12-31 | ₩699.50 Billion ≈ $474.04 Million |
₩76.99 Billion ≈ $52.18 Million |
0.110x | +21.74% |
| 2018-12-31 | ₩727.72 Billion ≈ $493.17 Million |
₩65.80 Billion ≈ $44.59 Million |
0.090x | -2.01% |
| 2017-12-31 | ₩695.71 Billion ≈ $471.47 Million |
₩64.19 Billion ≈ $43.50 Million |
0.092x | -48.33% |
| 2016-12-31 | ₩252.80 Billion ≈ $171.32 Million |
₩45.14 Billion ≈ $30.59 Million |
0.179x | +87.79% |
| 2015-12-31 | ₩207.85 Billion ≈ $140.85 Million |
₩19.76 Billion ≈ $13.39 Million |
0.095x | -52.12% |
| 2014-12-31 | ₩53.21 Billion ≈ $36.06 Million |
₩10.57 Billion ≈ $7.16 Million |
0.199x | -- |
About Hugel Inc
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more